Neurotherapeutic promise of egg‐derived antioxidants: mental health implications, and future perspectives

Mental illness conditions and neurodegenerative diseases are an emerging worldwide burden, with depression affecting over 300 million people and dementia cases projected to triple by 2050. Oxidative stress and inflammation are central mechanisms for neuronal injury and cognitive impairment. This review discusses the neurotherapeutic promise of egg-derived antioxidants. Importantly, yolk in polypeptide complex (isolated from egg yolk with immunoglobulin Y) enhances cognitive function by upregulating brain-derived neurotrophic factor via cAMP/PKA and PI3K/Akt signaling. We discuss their molecular modes of action such as reactive oxygen species scavenging, regulation of inflammatory cytokines, maintenance of mitochondrial function, and promotion of neurogenesis and synaptic plasticity. Further, bioavailability, allergenicity, and targeted delivery issues across the blood-brain barrier are addressed in light of progress in nanocarrier systems and encapsulation methods. Comparative observations with other diet-based antioxidants like curcumin, polyphenols, and omega-3 fatty acids are presented to put egg-derived compounds into perspective within the overall nutraceutical regime. Lastly, future directions highlight the importance of targeted clinical trials, regulatory factors, and inclusion in public health initiatives designed to prevent cognitive degeneration and mental illness through accessible nutritional interventions. This review highlights the promising potential of antioxidants derived from eggs as adjunctive neuroprotective therapy and indicates the need for interdisciplinary investigations to extend these findings into the clinic. © 2026 Society of Chemical Industry.